{"log_id": 6175329707620639072, "direction": 0, "words_result_num": 50, "words_result": [{"probability": {"variance": 0.031358, "average": 0.910195, "min": 0.416012}, "location": {"width": 503, "top": 214, "height": 49, "left": 263}, "words": "在儿童患者中,利奈唑的最大药浓度"}, {"probability": {"variance": 0.015343, "average": 0.887287, "min": 0.60521}, "location": {"width": 433, "top": 201, "height": 46, "left": 874}, "words": "和分布容!(Vss与年龄无关:利东"}, {"probability": {"variance": 0.030423, "average": 0.884596, "min": 0.413946}, "location": {"width": 1102, "top": 241, "height": 64, "left": 205}, "words": "唑肢的消除率与年龄。除了出生不到一同的新生,年龄最八的儿童组,即出牛一周后"}, {"probability": {"variance": 0.024774, "average": 0.915145, "min": 0.399968}, "location": {"width": 1102, "top": 281, "height": 67, "left": 208}, "words": "111岁年龄:与成人相比,清除速率最快,从而导烫了单剂给药后较低的全身药物"}, {"probability": {"variance": 0.014965, "average": 0.913262, "min": 0.470262}, "location": {"width": 1075, "top": 322, "height": 69, "left": 208}, "words": "录量(C)和较短的半衰随着儿童患若年龄增加,利奈唑胺的清除率逐渐降低"}, {"probability": {"variance": 0.014492, "average": 0.90779, "min": 0.564201}, "location": {"width": 1104, "top": 366, "height": 60, "left": 205}, "words": "青春期的儿童患的清率已与成年忌者的村,与成人相比,在所有不同龄层的儿童患"}, {"probability": {"variance": 0.034258, "average": 0.878012, "min": 0.365978}, "location": {"width": 791, "top": 413, "height": 58, "left": 212}, "words": "名中观察到清除率与全药物暴露量(C)存在更的个体差开"}, {"probability": {"variance": 0.025363, "average": 0.916738, "min": 0.398374}, "location": {"width": 1049, "top": 447, "height": 64, "left": 268}, "words": "新生儿至1岁的儿童患省每8小时给约一次日平均AUC值一青少年和成年患名每12"}, {"probability": {"variance": 0.024683, "average": 0.934291, "min": 0.369956}, "location": {"width": 1104, "top": 487, "height": 67, "left": 210}, "words": "小时给药一次的日平均AC值相似。而,11岁及小于1岁儿童患者的给药剂量应为"}, {"probability": {"variance": 0.02226, "average": 0.911258, "min": 0.479867}, "location": {"width": 1022, "top": 530, "height": 67, "left": 246}, "words": "g/kg,每8小时一次:12岁及其以上的儿童患者给药剂量为50mg每12小时一次"}, {"probability": {"variance": 0.00962, "average": 0.948728, "min": 0.637968}, "location": {"width": 1044, "top": 570, "height": 67, "left": 270}, "words": "出生后个到7天的早产儿小于34个孕周)的用药方案依9例早产儿的药代动"}, {"probability": {"variance": 0.033312, "average": 0.89664, "min": 0.379564}, "location": {"width": 1102, "top": 612, "height": 67, "left": 214}, "words": "力学数据与足月的新生儿不1较大的新生儿相比,大多数产儿的系统清除率较低,且AUC"}, {"probability": {"variance": 0.018502, "average": 0.922645, "min": 0.479233}, "location": {"width": 1104, "top": 655, "height": 64, "left": 214}, "words": "值较高。所以,早产儿的治疗应从10mg/kg,每12小时一次习始剂量开始:对临床上未"}, {"probability": {"variance": 0.018962, "average": 0.926384, "min": 0.495291}, "location": {"width": 1102, "top": 695, "height": 69, "left": 214}, "words": "取得最佳疗效的新生儿可比Cmg/kg每8小时一次的治疗方案。所有出生7天或以"}, {"probability": {"variance": 0.01576, "average": 0.935947, "min": 0.389055}, "location": {"width": 1100, "top": 738, "height": 64, "left": 221}, "words": "上的新生儿应10g/kg每8小正的剂量给药(见【药代动力学】一特殊人群、儿童和【用"}, {"probability": {"variance": 0.048868, "average": 0.865254, "min": 0.482413}, "location": {"width": 111, "top": 807, "height": 33, "left": 214}, "words": "法用量】"}, {"probability": {"variance": 0.045485, "average": 0.82976, "min": 0.377254}, "location": {"width": 1046, "top": 820, "height": 62, "left": 275}, "words": "在有限的临床经输中,6儿童忠名中的5例83%,利奈按对其感染的兰阳"}, {"probability": {"variance": 0.030112, "average": 0.904256, "min": 0.415847}, "location": {"width": 454, "top": 879, "height": 44, "left": 219}, "words": "性柄原体最低菌浓度MIC为"}, {"probability": {"variance": 0.022611, "average": 0.896129, "min": 0.425729}, "location": {"width": 532, "top": 861, "height": 49, "left": 735}, "words": "经利奈唑胺治疗得怡床痊愈。与成人比"}, {"probability": {"variance": 0.028471, "average": 0.888907, "min": 0.404172}, "location": {"width": 1102, "top": 901, "height": 64, "left": 221}, "words": "童者间利奈唑胺的清除率和全身药物露AUC)表现出主的个体司差。对获得最"}, {"probability": {"variance": 0.018194, "average": 0.924981, "min": 0.517384}, "location": {"width": 1107, "top": 939, "height": 67, "left": 221}, "words": "佳临床疗效的儿者,尤其对于利杂胺最低抑菌浓度为4ug/mL的原体,在评价临"}, {"probability": {"variance": 0.021599, "average": 0.938387, "min": 0.394468}, "location": {"width": 1102, "top": 981, "height": 64, "left": 223}, "words": "疗效时,应考虑到患儿较低的全身药物暴量,感染的部位及其严重程度以及其基础病:见"}, {"probability": {"variance": 2.6e-05, "average": 0.996132, "min": 0.983172}, "location": {"width": 601, "top": 1035, "height": 49, "left": 232}, "words": "【药代动力学】一特殊人群、儿童和【用法用量"}, {"probability": {"variance": 6.2e-05, "average": 0.993037, "min": 0.977761}, "location": {"width": 154, "top": 1129, "height": 31, "left": 234}, "words": "【老年用药】"}, {"probability": {"variance": 0.021699, "average": 0.917571, "min": 0.375156}, "location": {"width": 1042, "top": 1142, "height": 62, "left": 288}, "words": "在Ⅲ斯对照引究中,2046例患者接受了利奈唑治疗:其中58929%〕例为65岁"}, {"probability": {"variance": 0.008429, "average": 0.963881, "min": 0.649598}, "location": {"width": 342, "top": 1205, "height": 42, "left": 228}, "words": "或65岁以上的忠:253例"}, {"probability": {"variance": 0.027681, "average": 0.861088, "min": 0.435113}, "location": {"width": 700, "top": 1183, "height": 55, "left": 633}, "words": "患者年龄于等于75岁,未见利奈唑胺在这些患者一"}, {"probability": {"variance": 0.019822, "average": 0.937125, "min": 0.436115}, "location": {"width": 476, "top": 1243, "height": 44, "left": 228}, "words": "年轻患者之间有安全性和有效的差"}, {"probability": {"variance": 0.001006, "average": 0.985653, "min": 0.901816}, "location": {"width": 210, "top": 1330, "height": 40, "left": 239}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.085321, "average": 0.661588, "min": 0.36949}, "location": {"width": 134, "top": 1310, "height": 53, "left": 1241}, "words": "分"}, {"probability": {"variance": 0.006654, "average": 0.95554, "min": 0.686666}, "location": {"width": 413, "top": 1368, "height": 44, "left": 237}, "words": "通过细胞色酶P450代的药物"}, {"probability": {"variance": 0.003277, "average": 0.973289, "min": 0.74373}, "location": {"width": 512, "top": 1404, "height": 46, "left": 290}, "words": "在大鼠中,利奈唑按不是细胞色素酶P450"}, {"probability": {"variance": 0.008637, "average": 0.92906, "min": 0.713627}, "location": {"width": 436, "top": 1389, "height": 46, "left": 901}, "words": "0)诱导剂,另外,利唑胺不抑"}, {"probability": {"variance": 0.037851, "average": 0.851257, "min": 0.369712}, "location": {"width": 1008, "top": 1429, "height": 67, "left": 237}, "words": "制有临床意义的人类细胞色同(如1A2,2C9:2C1号,2D6,2E1和3特的活性"}, {"probability": {"variance": 0.019842, "average": 0.912038, "min": 0.472418}, "location": {"width": 1073, "top": 1469, "height": 67, "left": 237}, "words": "预订利奈唑安不会影响经这主要细孢色素同上前代谢的药物的药代动力学与利奈吗"}, {"probability": {"variance": 0.015892, "average": 0.935423, "min": 0.437365}, "location": {"width": 1078, "top": 1512, "height": 64, "left": 239}, "words": "合药,不会显著改变主要由CYP2C9进行代谢的(S)-华法从的药代动力学性华法林"}, {"probability": {"variance": 0.025479, "average": 0.903524, "min": 0.375031}, "location": {"width": 955, "top": 1556, "height": 62, "left": 237}, "words": "苯妥丙等药,牛为CYP2C9的底物,可与奈唑合用无改变药方案"}, {"probability": {"variance": 0.001661, "average": 0.958833, "min": 0.894729}, "location": {"width": 93, "top": 1621, "height": 33, "left": 241}, "words": "抗生素:"}, {"probability": {"variance": 0.036042, "average": 0.871457, "min": 0.48068}, "location": {"width": 917, "top": 1635, "height": 64, "left": 299}, "words": "氨瘤南:当者合用时,利奈发与氨曲南的药代动方学特唑均未发生改变"}, {"probability": {"variance": 0.020622, "average": 0.899639, "min": 0.481178}, "location": {"width": 977, "top": 1677, "height": 62, "left": 299}, "words": "庆大索:当二者合用时,利余唑与庆人霉的药代动力学特性均未发改变"}, {"probability": {"variance": 0.033999, "average": 0.883557, "min": 0.374871}, "location": {"width": 1044, "top": 1715, "height": 67, "left": 304}, "words": "利:在一项对16名洪康成人男性志愿者进行的研究中,评价了利福平对利杂唑胺"}, {"probability": {"variance": 0.035599, "average": 0.876688, "min": 0.371231}, "location": {"width": 1107, "top": 1758, "height": 64, "left": 243}, "words": "药代动力学响引究中志老口服利奈唑60mng日2次共5剂,伴或不半利福平600mg"}, {"probability": {"variance": 0.039754, "average": 0.835516, "min": 0.377268}, "location": {"width": 764, "top": 1805, "height": 60, "left": 246}, "words": "每H1次共8天。利福平和利奈胺合用,号致奈核的"}, {"probability": {"variance": 0.020996, "average": 0.903555, "min": 0.61677}, "location": {"width": 241, "top": 1805, "height": 31, "left": 1100}, "words": "降低21%[90%CI"}, {"probability": {"variance": 0.033149, "average": 0.854778, "min": 0.352604}, "location": {"width": 1102, "top": 1838, "height": 67, "left": 250}, "words": "5%-27%,AICn12降低32%90%CL.27-37%]:这一相互作用的机制未完全明,可能"}, {"probability": {"variance": 0.017024, "average": 0.932879, "min": 0.494928}, "location": {"width": 657, "top": 1894, "height": 49, "left": 272}, "words": "肝酶添导有关(见【注意事项】中的药物相互作用"}, {"probability": {"variance": 0.010595, "average": 0.907726, "min": 0.694368}, "location": {"width": 259, "top": 1945, "height": 40, "left": 250}, "words": "单胺氧化抑制作用"}, {"probability": {"variance": 0.027825, "average": 0.190857, "min": 0.024048}, "location": {"width": 116, "top": 1921, "height": 42, "left": 1149}, "words": " OUSIA"}, {"probability": {"variance": 0.036165, "average": 0.842223, "min": 0.360126}, "location": {"width": 1049, "top": 1961, "height": 69, "left": 308}, "words": "利奈可的、非选择性的单按氧化酶抑制剂。所以,唑腺素能药物"}, {"probability": {"variance": 0.001079, "average": 0.973604, "min": 0.892448}, "location": {"width": 192, "top": 2022, "height": 29, "left": 706}, "words": "第13页,共25页"}], "language": 3}